On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

On location

Examining Pregnancy Outcomes in Eculizumab-Treated Women With Atypical Hemolytic Uremic Syndrome

Women with atypical hemolytic uremic syndrome (aHUS) treated with eculizumab have similar pregnancy outcomes to women who were not treated with eculizumab, according to...
On location

Patients With Hemophilia B Report Poor Bleeding Control With Extended Half-Life Factor IX Products

Extended half-life factor IX (FIX) products have been designed to prolong the time between clotting factor injections for patients with hemophilia B, but an...
On location

Two Studies Support Using Concizumab as Prophylaxis in Patients With Hemophilia

Concizumab could be a safe and effective subcutaneous prophylactic treatment option for patients with hemophilia A or B with or without inhibitors, according to...
On location

Hemophilia B: The Next Target for Gene Therapy?

Treatment with a single dose of AMT-061, an investigational gene therapy, led to increased factor IX (FIX) activity and reduced spontaneous bleeding episodes for...
You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you treat relapsed/refractory myeloma after transplant?

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
You Make the Call

From ASH Meeting on Hematologic Malignancies: What are the approved options for relapsed marginal...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
You Make the Call

From ASH Meeting on Hematologic Malignancies: How would you treat this patient with high-grade...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
On location

Isatuximab Combination Improves Progression-Free Survival in Pretreated Myeloma

The combination of isatuximab and pomalidomide plus dexamethasone (Pd) extended progression-free survival (PFS) to 11.5 months in patients with relapsed/refractory multiple myeloma (MM) –...
On location

Guadecitabine Performs No Better Than Other Hypomethylating Agents in Treatment-Naïve Acute Myeloid Leukemia

Results from a large phase III trial of the hypomethylating agent (HMA) guadecitabine in patients with treatment-naïve acute myeloid leukemia (AML) show that this...
On location

Valoctocogene Roxaparvovec Continues to Improve Bleeding Outcomes in Patients with Hemophilia A

In three-year follow-up results from an ongoing phase I/II study of patients with hemophilia A, valoctocogene roxaparvovec gene therapy significantly reduced annual bleeding rates...
Advertisement

Current Issue

October 2019, Volume 5, Issue 12

This issue highlights the unintended consequences of fighting the nation’s opioid epidemic, considers the optimal frontline regimen for myeloma, and more.